Notice to the media - Government of Canada officials to hold a technical briefing on coronavirus disease in Canada
OTTAWA, ON, July 30, 2021 /CNW/ - Government of Canada officials will hold a media technical briefing on data and modelling.
Officials will be available to answer questions from the media following their remarks.
Date July 30, 2021
Time 11:00 AM (EDT)
Location
The media technical briefing will be held virtually.
Media will be able to ask questions via teleconference.
Toll-free (Canada/US) dial-in number: 1-866-206-0153 Local dial-in number: 613-954-9003
Passcode: 1622050#
To obtain the briefing material under embargo, please RSVP by email at [email protected].
NOTE: To help ensure optimal simultaneous interpretation sound quality, journalists are encouraged to use a microphone (headphones/headset) or, when possible, a landline, and to avoid using speaker mode if queuing up for questions.
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
CancerVision and...
